RJFSA
AVXL icon

Raymond James Financial Services Advisors’s Anavex Life Sciences AVXL Stock Holding History

Raymond James Financial Services Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$69.7K Buy
+12,275
New +$70.8K ﹤0.01% 3337
2023
Q4 		– Sell
-31,155
Closed -$204K – 3309
2023
Q3 		$204K Sell
31,155
-2,165
-6% -$17.2K ﹤0.01% 2923
2023
Q2 		$271K Buy
33,320
+1,300
+4% +$11.1K ﹤0.01% 2730
2023
Q1 		$274K Sell
32,020
-46
-0.1% -$459 ﹤0.01% 2707
2022
Q4 		$297K Buy
32,066
+1,796
+6% +$19.2K ﹤0.01% 2589
2022
Q3 		$312K Buy
30,270
+2,500
+9% +$26.4K ﹤0.01% 2543
2022
Q2 		$278K Buy
27,770
+2,000
+8% +$18.9K ﹤0.01% 2642
2022
Q1 		$317K Buy
25,770
+1,561
+6% +$19.2K ﹤0.01% 2675
2021
Q4 		$420K Buy
24,209
+1,000
+4% +$19K ﹤0.01% 2487
2021
Q3 		$417K Sell
23,209
-35,362
-60% -$704K ﹤0.01% 2481
2021
Q2 		$1.34M Buy
58,571
+2,644
+5% +$39.2K ﹤0.01% 1741
2021
Q1 		$836K Sell
55,927
-6,493
-10% -$70.9K ﹤0.01% 1971
2020
Q4 		$337K Buy
62,420
+15,000
+32% +$79K ﹤0.01% 2396
2020
Q3 		$216K Buy
47,420
+11,000
+30% +$47.3K ﹤0.01% 2494
2020
Q2 		$179K Sell
36,420
-2,830
-7% -$10.7K ﹤0.01% 2526
2020
Q1 		$124K Buy
39,250
+20,000
+104% +$69.7K ﹤0.01% 2192
2019
Q4 		$50K Hold
19,250
– – ﹤0.01% 2760
2019
Q3 		$61K Sell
19,250
-1,500
-7% -$4.33K ﹤0.01% 2690
2019
Q2 		$70K Buy
20,750
+5,500
+36% +$17.1K ﹤0.01% 2718
2019
Q1 		$47K Hold
15,250
– – ﹤0.01% 2708
2018
Q4 		$24K Hold
15,250
– – ﹤0.01% 2506
2018
Q3 		$42K Buy
+15,250
New +$43K ﹤0.01% 2726

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial Services Advisors's AVXL Position: Q3 2024 in Review

Raymond James Financial Services Advisors opened a new position in Anavex Life Sciences (AVXL) in Q3 2024: 12,275 shares worth $69.7K. The stake represents ﹤0.01% of the portfolio and ranks #3337 among its holdings. This is a return to the name: Raymond James Financial Services Advisors previously reported a position in AVXL as recently as Q3 2023.

Raymond James Financial Services Advisors first reported a position in AVXL in Q3 2018 and has held it in 22 quarters since. The position peaked at $1.34M in Q2 2021. 145 funds tracked by Wall St. Rank hold AVXL as of Q3 2024.

  • Raymond James Financial Services Advisors held 12,275 shares of Anavex Life Sciences worth $69.7K as of Q3 2024.
  • Anavex Life Sciences was a new Raymond James Financial Services Advisors position in Q3 2024.
  • Anavex Life Sciences made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3337 holding.
  • Raymond James Financial Services Advisors first reported a position in Anavex Life Sciences in Q3 2018 and has held it in 22 quarters since.
  • Raymond James Financial Services Advisors's Anavex Life Sciences position peaked at $1.34M in Q2 2021.
  • 145 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.